Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell therapy shows promise for Post-Transplant cancer

NCT ID NCT00033475

Disease control Sponsor: University of Edinburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether specially treated donor white blood cells could help treat a type of lymph cancer that sometimes occurs after an organ transplant. The cancer is linked to the Epstein-Barr virus. Fifty transplant recipients took part. The goal was to see if adding these donor cells to standard care (reducing immune-suppressing drugs) led to better tumor shrinkage and survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2001

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

DISEASE CHARACTERISTICS: * Diagnosis of post-transplant lymphoproliferative disease (PTLD) after solid organ (heart, heart/lung, liver, liver/gut, pancreas, or kidney) transplantation * Epstein-Barr virus-positive tumor * Newly diagnosed disease * Measurable disease by clinical methods or radiography * Must have partially matched donor cytotoxic T cells (CTL) available * No known panel reactivity to any of the HLA types of CTL available for therapy PATIENT CHARACTERISTICS: Age: * Any age Performance status: * Karnofsky 20-100% Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified Other: * Not pregnant PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * Not specified Endocrine therapy: * Not specified Radiotherapy: * Not specified Surgery: * Not specified Other: * No prior therapy for PTLD * No concurrent antiviral drugs (e.g., acyclovir or ganciclovir) for PTLD

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphoproliferative disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymphoproliferative syndrome post-transplant lymphoproliferative disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoproliferative disorder

Contacts and locations

Locations

  • Birmingham Children's Hospital

    Birmingham, England, B4 6NH, United Kingdom

  • Central Manchester and Manchester Children's University Hospitals NHS Trust

    Manchester, England, M27 4HA, United Kingdom

  • Institute of Cancer Research - UK

    Sutton, England, SM2 5NG, United Kingdom

  • King's College Hospital

    London, England, SE5 8RX, United Kingdom

  • Northern General Hospital

    Sheffield, England, S5 7AU, United Kingdom

  • Papworth Hospital

    Cambridge, England, CB3 8RE, United Kingdom

  • Royal Free and University College Medical School

    London, England, NW3 2PF, United Kingdom

  • Royal Infirmary - Castle

    Glasgow, Scotland, G4 0SF, United Kingdom

  • Royal Infirmary of Edinburgh at Little France

    Edinburgh, Scotland, EH16 4SA, United Kingdom

  • University of Edinburgh

    Edinburgh, Scotland, EH8 1QH, United Kingdom

  • University of Edinburgh Laboratory for Clinical and Molecular Virology

    Edinburgh, Scotland, EH9 1QH, United Kingdom

  • Wythenshawe Hospital

    Manchester, England, M23 9LJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.